from Reuters: Health News https://ift.tt/2TqjEF8
Sunday, March 24, 2019
Sunday, March 24, 2019
MZ Digital Marketing Agency
HEALTH NEWS
No comments
Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday.

from Reuters: Health News https://ift.tt/2TqjEF8
from Reuters: Health News https://ift.tt/2TqjEF8
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment